These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17145251)

  • 1. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
    Hull RD; Pineo GF; Brant RF; Mah AF; Burke N; Dear R; Wong T; Cook R; Solymoss S; Poon MC; Raskob G;
    Am J Med; 2006 Dec; 119(12):1062-72. PubMed ID: 17145251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
    Hull RD; Pineo GF; Brant RF; Mah AF; Burke N; Dear R; Wong T; Cook R; Solymoss S; Poon MC; Raskob G;
    Am J Med; 2007 Jan; 120(1):72-82. PubMed ID: 17208082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
    Hull RD; Pineo GF; Brant R; Liang J; Cook R; Solymoss S; Poon MC; Raskob G;
    Am J Med; 2009 Aug; 122(8):762-769.e3. PubMed ID: 19635277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer].
    Romera-Villegas A; Martí Mestre X; Vila Coll R; Colomé Nafría E
    Med Clin (Barc); 2015 Jan; 144 Suppl 1():16-20. PubMed ID: 25771087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
    Romera A; Cairols MA; Vila-Coll R; Martí X; Colomé E; Bonell A; Lapiedra O
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):349-56. PubMed ID: 19121589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
    Hyers TM; Spyropoulos AC;
    J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
    Daskalopoulos ME; Daskalopoulou SS; Tzortzis E; Sfiridis P; Nikolaou A; Dimitroulis D; Kakissis I; Liapis CD
    Eur J Vasc Endovasc Surg; 2005 Jun; 29(6):638-50. PubMed ID: 15878544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
    Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
    Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
    Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
    Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Elliott G; Stein PD; Gottschalk A; Valentine KA; Mah AF
    Arch Intern Med; 2000 Jan; 160(2):229-36. PubMed ID: 10647762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
    Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study.
    Hull RD; Liang J; Merali T
    Clin Appl Thromb Hemost; 2013 Sep; 19(5):476-81. PubMed ID: 23520150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.